Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 8:19:83-96.
doi: 10.2147/DDDT.S500719. eCollection 2025.

A Review of the Therapeutic Potential of Ginseng and Its Bioactive Components in Nonalcoholic Fatty Liver Disease

Liyuan Hao #  1   2 , Shenghao Li #  1   2   3 , Caige Li  4 , Zhiqin Zhang  5 , Xiaoyu Hu  2 , Huimin Yan  3
Affiliations
Review

A Review of the Therapeutic Potential of Ginseng and Its Bioactive Components in Nonalcoholic Fatty Liver Disease

Liyuan Hao et al. Drug Des Devel Ther. .

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the major cause of chronic liver disease worldwide, with no universally recognized effective treatments currently available. In recent years, ginseng and its principal active components, such as ginsenosides, have shown potential protective effects in the treatment of these liver diseases. In NAFLD, studies have demonstrated that ginseng can improve hepatic lipid metabolism, reduce inflammatory responses, and inhibit oxidative stress and fibrosis, thereby attenuating the progression of NAFLD. Additionally, ginseng inhibits oxidative stress by scavenging free radicals and enhancing antioxidant enzyme activities, and it can impede fibrosis by interfering with the fibrotic signaling pathways. These combined effects contribute to attenuating the progression of NAFLD. These findings highlight the promise of ginseng as a potential therapeutic candidate for the treatment of NAFLD. However, despite the significant efficacy of ginseng in human NAFLD treatment, the number and quality of clinical studies remain limited, with a lack of large-scale, multicenter clinical trials to confirm these effects. Moreover, the pharmacokinetic properties of different ginsenosides, optimal therapeutic dosages, and the safety of long-term use require further investigation. This review summarizes the existing evidence on the mechanisms of action of ginseng and its active components in human NAFLD, assesses their potential as therapeutic options, and proposes future research directions to provide stronger scientific support for clinical application. Additionally, we performed a network pharmacology analysis of ginseng in relation to NAFLD to identify and investigate potential targets of ginseng in the treatment of NAFLD. This analysis aims to provide a theoretical foundation for the development of ginseng -based drugs for combating NAFLD.

Keywords: NAFLD; NASH; bioactive components; ginseng.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Protective effect of ginseng and its components on NAFLD.
Figure 2
Figure 2
Mechanism of ginseng and its components against NAFLD.
Figure 3
Figure 3
Identification of key targets. (A) Venn diagram of ginseng and NAFLD. (B) PPI networks of key targets. (C) Top 10 key targets.
Figure 4
Figure 4
GO and KEGG. (A) GO analysis of intersection targets. (B) KEGG analysis of intersection targets.
See this image and copyright information in PMC

References

    1. Guo X, Yin X, Liu Z, Wang J. Non-Alcoholic Fatty Liver Disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci. 2022;23(24). doi:10.3390/ijms232415489 - DOI - PMC - PubMed
    1. Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol. 2022;22(7):429–443. doi:10.1038/s41577-021-00639-3 - DOI - PMC - PubMed
    1. Zhou J, Zhang J, Jing P, et al. Ginseng in white and red processed forms: ginsenosides and cardiac side effects. Food Sci Nutr. 2024;12(3):1857–1868. doi:10.1002/fsn3.3879 - DOI - PMC - PubMed
    1. Zhang J, Duan M, Wu S, et al. Comprehensive pharmacological and experimental study of Ginsenoside Re as a potential therapeutic agent for non-alcoholic fatty liver disease. Biomed Pharmacother. 2024;177:116955. doi:10.1016/j.biopha.2024.116955 - DOI - PubMed
    1. Kim JC, Jeon JY, Yang WS, Kim CH, Eom DW. Combined amelioration of ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean red ginseng and probiotic lactobacillus on non-alcoholic fatty liver disease. Current Pharm Biotechnol. 2019;20(3):222–231. doi:10.2174/1389201020666190311143554 - DOI - PubMed

MeSH terms

LinkOut - more resources